Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2025 09:32 ET | Source: Polyrizon Ltd.

Polyrizon Ltd. Announces $17.0 Million Private Placement

RAANANA, ISRAEL, March 31, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced that it has...
March 27, 2025 08:25 ET | Source: Polyrizon Ltd.

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd....
March 25, 2025 16:04 ET | Source: Polyrizon Ltd.

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Raanana, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative...
March 14, 2025 08:35 ET | Source: Polyrizon Ltd.

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative...
March 13, 2025 07:51 ET | Source: Polyrizon Ltd.

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative...
March 11, 2025 16:27 ET | Source: Polyrizon Ltd.

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Raanana, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative...
March 10, 2025 07:47 ET | Source: Polyrizon Ltd.

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative...
January 30, 2025 05:55 ET | Source: Polyrizon Ltd.

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative...
January 23, 2025 06:40 ET | Source: Polyrizon Ltd.

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the...
December 30, 2024 06:25 ET | Source: Polyrizon Ltd.

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right